Compare ACADIA Pharmaceuticals Inc. (ACAD) vs American Homes 4 Rent Class A (AMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs American Homes 4 Rent Class A — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.5 (market cap $5.07B), while American Homes 4 Rent Class A trades at $33.72 (market cap $12.28B). The key difference: American Homes 4 Rent Class A is far larger — about 2.4× ACADIA Pharmaceuticals Inc.'s market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AMH | |
|---|---|---|
Market Cap | $5.07B | $12.28B |
Sector | Health | Real Estate |
52-Week High | $29.41 | $35.82 |
52-Week Low | $20.06 | $27.38 |
Enterprise Value | $4.19B | $17.35B |
Dividend Yield | — | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
AMH trades at $34.13, down 1.44% on the day, with a bullish technical signal from moving averages and a consensus price target of $36.45. The company reported strong Q2 2026 earnings, beating FFO and revenue estimates, and raised full-year guidance. Revenue grew to $1.85B in 2025, with net income margin improving to 25.53%. A dividend of $0.33 per share is scheduled for payment on June 30, 2026.
Outlook is positive with consistent earnings beats and raised guidance, but risks include high debt levels and regulatory impacts from new housing legislation. Institutional sentiment remains supportive with no sell ratings among analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →
